Provided by Tiger Fintech (Singapore) Pte. Ltd.

Korro Bio, Inc.

13.90
+0.44003.27%
Post-market: 13.900.00000.00%18:15 EDT
Volume:84.63K
Turnover:1.15M
Market Cap:130.51M
PE:-1.48
High:13.94
Open:13.41
Low:13.06
Close:13.46
Loading ...

Korro Bio Inc - CEO Ram Aiyar Appointed Interim Principal Financial Officer

THOMSON REUTERS
·
12 Feb

Korro Bio announces initiation of dosing in its REWRITE study on KRRO-110

TIPRANKS
·
13 Jan

Korro Bio Announces Dosing of First Participants in Rewrite Phase 1/2a Study of Krro-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update

THOMSON REUTERS
·
13 Jan

Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update

GlobeNewswire
·
13 Jan

Oppenheimer Initiates Korro Bio at Outperform With $155 Price Target

MT Newswires Live
·
10 Jan

Why Korro Bio (KRRO) Should Be on Your Investment Radar

TIPRANKS
·
10 Dec 2024

Korro Bio Files Mixed Shelf Registration

MT Newswires Live
·
03 Dec 2024

Korro Bio Inc Files for Mixed Shelf of up to $400 Mln – SEC Filing

THOMSON REUTERS
·
03 Dec 2024

Korro Bio: “at Market Offering” Prospectus Offering of up to $100 Mln Common Stock That May Be Issued From Time to Time

THOMSON REUTERS
·
03 Dec 2024

We Think Korro Bio (NASDAQ:KRRO) Needs To Drive Business Growth Carefully

Simply Wall St.
·
29 Nov 2024

Korro Bio Price Target Maintained With a $115.00/Share by HC Wainwright & Co.

Dow Jones
·
22 Nov 2024

BRIEF-Korro Receives Australian HREC Approval and CTN Clearance

Reuters
·
21 Nov 2024

Korro Bio Inc - First Participant Dosing Expected in Q1 2025

THOMSON REUTERS
·
21 Nov 2024

Korro Receives Australian Hrec Approval and Ctn Clearance to Initiate Phase 1/2a Clinical Study (Rewrite) of Krro-110 for Alpha-1 Antitrypsin Deficiency

THOMSON REUTERS
·
21 Nov 2024

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

GlobeNewswire
·
21 Nov 2024

JonesTrading Initiates Korro Bio at Buy With $130 Price Target

MT Newswires Live
·
18 Nov 2024

Korro Bio initiated with a Buy at JonesResearch

TIPRANKS
·
18 Nov 2024

U.S. RESEARCH ROUNDUP- Airbnb, Post Holdings, Syndax Pharmaceuticals

Reuters
·
18 Nov 2024

Korro Bio Inc : Jonestrading Initiates Coverage With Buy Rating; Target Price $130

THOMSON REUTERS
·
18 Nov 2024

Korro Bio Price Target Maintained With a $115.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Nov 2024